Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
Adolescent
Adult
Chimerism
Female
Fetal Blood
/ transplantation
Graft vs Host Disease
/ etiology
Humans
Immunotherapy, Adoptive
/ adverse effects
Infections
/ etiology
Leukemia, Myeloid, Acute
/ complications
Male
Middle Aged
Myelodysplastic Syndromes
/ complications
Prospective Studies
Salvage Therapy
Treatment Outcome
Adoptive immunotherapy
Cell therapy
Cord blood
Refractory acute myelogenous leukemia
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
07
09
2018
accepted:
01
11
2018
pubmed:
12
11
2018
medline:
29
1
2020
entrez:
12
11
2018
Statut:
ppublish
Résumé
Adoptive immunotherapy has shown efficacy in patients with relapsed/refractory acute myelogenous leukemia (AML). We conducted a prospective evaluation of cord blood (CB)-based adoptive cell therapy following salvage chemotherapy in patients with AML or myelodysplastic syndrome (MDS) and describe the safety and early outcomes of this approach. To enhance the antileukemic effect, we selected CB units (CBUs) with a shared inherited paternal antigen (IPA) and/or noninherited maternal antigen (NIMA) match with the recipients. Furthermore, the CBUs had total nucleated cell (TNC) dose <2.5 × 10
Identifiants
pubmed: 30414955
pii: S1083-8791(18)30695-5
doi: 10.1016/j.bbmt.2018.11.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
466-473Informations de copyright
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.